Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells.

Agra N, Cidre F, García-García L, de la Parra J, Alonso J.

PLoS One. 2013 Jun 4;8(6):e66281. doi: 10.1371/journal.pone.0066281. Print 2013.

2.

Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.

Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL.

Oncogene. 2013 Oct 17;32(42):5089-100. doi: 10.1038/onc.2012.525. Epub 2012 Nov 26.

3.

High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.

He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K.

Gene. 2017 Jan 5;596:137-146. doi: 10.1016/j.gene.2016.10.021. Epub 2016 Oct 17.

PMID:
27760381
4.

Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.

Gierisch ME, Pfistner F, Lopez-Garcia LA, Harder L, Schäfer BW, Niggli FK.

J Biol Chem. 2016 Dec 23;291(52):26922-26933. doi: 10.1074/jbc.M116.752063. Epub 2016 Nov 8.

PMID:
27875302
5.

Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.

Herrero-Martín D, Osuna D, Ordóñez JL, Sevillano V, Martins AS, Mackintosh C, Campos M, Madoz-Gúrpide J, Otero-Motta AP, Caballero G, Amaral AT, Wai DH, Braun Y, Eisenacher M, Schaefer KL, Poremba C, de Alava E.

Br J Cancer. 2009 Jul 7;101(1):80-90. doi: 10.1038/sj.bjc.6605104. Epub 2009 Jun 2.

6.

FOXM1 is an oncogenic mediator in Ewing Sarcoma.

Christensen L, Joo J, Lee S, Wai D, Triche TJ, May WA.

PLoS One. 2013;8(1):e54556. doi: 10.1371/journal.pone.0054556. Epub 2013 Jan 24.

7.

A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.

Leacock SW, Basse AN, Chandler GL, Kirk AM, Rakheja D, Amatruda JF.

Dis Model Mech. 2012 Jan;5(1):95-106. doi: 10.1242/dmm.007401. Epub 2011 Oct 6.

8.

A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.

McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK, Jedlicka P.

Oncogene. 2011 Dec 8;30(49):4910-20. doi: 10.1038/onc.2011.197. Epub 2011 Jun 6.

9.

Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.

Jully B, Vijayalakshmi R, Gopal G, Sabitha K, Rajkumar T.

BMC Cancer. 2012 Nov 12;12:513. doi: 10.1186/1471-2407-12-513.

10.

RUNX3 facilitates growth of Ewing sarcoma cells.

Bledsoe KL, McGee-Lawrence ME, Camilleri ET, Wang X, Riester SM, van Wijnen AJ, Oliveira AM, Westendorf JJ.

J Cell Physiol. 2014 Dec;229(12):2049-56. doi: 10.1002/jcp.24663.

11.

Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.

Erkizan HV, Scher LJ, Gamble SE, Barber-Rotenberg JS, Sajwan KP, Üren A, Toretsky JA.

Cell Cycle. 2011 Oct 1;10(19):3397-408. doi: 10.4161/cc.10.19.17734. Epub 2011 Oct 1.

12.

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.

Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y.

Clin Cancer Res. 2015 Sep 15;21(18):4184-93. doi: 10.1158/1078-0432.CCR-14-2112. Epub 2015 Mar 16.

13.

Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.

De Vito C, Riggi N, Suvà ML, Janiszewska M, Horlbeck J, Baumer K, Provero P, Stamenkovic I.

PLoS One. 2011;6(8):e23592. doi: 10.1371/journal.pone.0023592. Epub 2011 Aug 10.

14.

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.

Theisen ER, Pishas KI, Saund RS, Lessnick SL.

Oncotarget. 2016 Apr 5;7(14):17616-30. doi: 10.18632/oncotarget.7124. Review.

15.

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.

Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.

Oncotarget. 2016 Jan 12;7(2):1451-63. doi: 10.18632/oncotarget.6385.

16.

Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.

Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H.

Oncogene. 2014 Jul 24;33(30):3927-38. doi: 10.1038/onc.2013.361. Epub 2013 Sep 2.

17.

Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone.

Park H, Turkalo TK, Nelson K, Folmsbee SS, Robb C, Roper B, Azuma M.

Cell Cycle. 2014;13(15):2391-9. doi: 10.4161/cc.29337.

18.

MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.

Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O.

Oncogene. 2013 Aug 15;32(33):3915-21.

PMID:
22986530
19.

PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.

Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000.

20.

Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.

Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ.

Cell Rep. 2016 Jan 26;14(3):598-610. doi: 10.1016/j.celrep.2015.12.063. Epub 2016 Jan 14.

Supplemental Content

Support Center